# OnCo record cinnagen (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/cinnagen/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "cinnagen" ;
  schema:name "CinnaGen"@en ;
  schema:alternateName "CinnaGen Co."@en, "Cinnagen"@en, "سیناژن"@en, "CinnaGen Pharmaceutical Group"@en ;
  schema:description "An Iranian maker of biological medicines, including copies of cancer antibodies, whose own pertuzumab copy matched the original in a phase 3 breast cancer trial."@en ;
  schema:url <https://onco.cc/companies/cinnagen/>, <https://www.cinnagen.com> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://web.archive.org/web/20260930035205/https://www.cinnagen.com/about-us/>, <https://clinicaltrials.gov/study/NCT04957212>, <https://doi.org/10.1186/s12885-022-09895-5> ;
  schema:addressCountry "IR" ;
  onco:cancers <https://onco.cc/cancers/breast-her2-positive/> ;
  onco:technologies <https://onco.cc/technologies/biosimilar-manufacturing/> ;
  onco:drugs <https://onco.cc/drugs/pertuzumab/> ;
  onco:companies <https://onco.cc/companies/aryogen-pharmed/> ;
  onco:terms <https://onco.cc/terms/biosimilar/> ;
  onco:trials <https://onco.cc/trials/nct04957212/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-p013-pertuzumab-biosimilar-bmc-cancer-2022/> .